{"id":"0690a310-4612-5098-9646-c6f2bbb4e396","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-ck2-earlier","predicate":"decreases_in_recorded_comparison","statement":"Apigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"64f1fcde-ff93-5341-b05f-045492327758","mechanism_event_label":"Apigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"evidence_count":1,"mechanism_event":{"id":"64f1fcde-ff93-5341-b05f-045492327758","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-ck2-earlier-event","event_type":"biochemical_relationship","label":"Apigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.","description":"### api-ck2-earlier\n\nApigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.\n\nModel and exposure: Human recombinant alpha-prime and beta subunits; ATP-incorporation assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. | 2009 | https://pubmed.ncbi.nlm.nih.gov/19197122/ | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin concentration series","sequence_order":0,"notes":""},{"entity":{"id":"8c3eb79c-4a30-5a53-a409-e1c4a4cea639","slug":"human-ck2-alpha-prime-holoenzyme","display_name":"Human CK2 alpha-prime/beta reconstituted holoenzyme","entity_type_key":"protein_complex"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"58b974f1-d389-5bf6-81cd-889c44442c42","slug":"atp","display_name":"ATP","entity_type_key":"small_molecule"},"role":"phosphoryl donor","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin concentration series\", \"comparator\": \"No inhibitor\", \"endpoint\": \"Apigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human recombinant alpha-prime and beta subunits; ATP-incorporation assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. | https://pubmed.ncbi.nlm.nih.gov/19197122/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-ck2-earlier; ","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"6ac1d90c-ca74-5535-bcbd-9b30ecc364b5","evidence_kind":"source_excerpt","locator":"Lines 592-598","start_line":592,"end_line":598,"excerpt":"### api-ck2-earlier\n\nApigenin inhibited reconstituted human CK2 alpha-prime/beta with IC50 1.72 micromolar in the earlier assay.\n\nModel and exposure: Human recombinant alpha-prime and beta subunits; ATP-incorporation assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. | 2009 | https://pubmed.ncbi.nlm.nih.gov/19197122/ | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Human recombinant alpha-prime and beta subunits; ATP-incorporation assay.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}